Kornimate/medical-research-clean huggingface dataset:
effect of a brace on the adolescent idiopathic scoliosis breathing

Conditions: Adolescent Idiopathic Scoliosis

Summary: this study intends to investigate the effect of bracing on respiratory function in the treatment of adolescent idiopathic scoliosis (ais). in particular, it will look at the effect of the brace on respiratory function and 3d volume of the thoracic cage. an additional evaluation of the pressure forces of the brace, using a connected t-shirt, will be carried out. the investigators hypothesise that the brace will decrease the respiratory parameters and 3d volume of the thoracic cage, especially during deep breathing.

scoliosis is a 3d deformity of the spine with curvatures occurring in the three planes of space. the brace is widely used for adolescent idiopathic scoliosis. the cheneau-toulouse-munster (ctm) brace is a rigid brace, classically indicated for thoracic and lumbar curves. however, scoliosis induces structural deformation of the rib cage. this can lead to changes in thoracic volume associated with a respiratory disorder, mainly restrictive. but the effect of bracing on pulmonary function currently remains unclear. few studies in the literature have looked at the impact of the brace on lung function. in those studies, the findings were based on pulmonary function test (pft) results only. in the ctm biomec study, the investigators propose to evaluate lung function by pft associated with biplanar radiography using eos® system, which allows 3d modelling of the rib cage. an additional evaluation of the pressure forces of the ctm brace, using a connected t-shirt, will be carried out to better understand the biomechanics of the brace. it will allow us to observe the stress surfaces on the thorax during the respiratory cycle and to compare them with the adaptation kinematics of the thoracic cage.

Eligibility criteria:
inclusion criteria: * adolescent girls aged 12 to 16 * with a right thoracic or thoraco-lumbar curvature (right and left) * with a cobb angle between 20 and 40°. * treated with a cheneau-toulouse-munster brace for more than 1 month * with a duration of brace wearing of more than 12/24h * affiliated to a social security system exclusion criteria: * male gender * having a secondary scoliosis (neuromuscular, syndromic, post-traumatic, congenital pathology) * having a respiratory pathology prior to the diagnosis of scoliosis * have a history of spinal surgery * having already benefited from a brace treatment

Keywords: adolescent female biomechanical phenomena
effects of diet on pregnancy outcome and child obesity

Conditions: Pregnancy Related; Diet Modification; Obesity; Hypertension; Pre-Eclampsia; Blood Pressure; Breast Feeding; Birth Weight

Summary: the purpose of the study is to compare 3 different diets in pregnancy, equal in calories, and fats, different in refined grains compared to whole grains as a source of carbohydrates, and in calories from carbohydrate, compared to protein as a source of calories.the hypothesis is that there will be differences in the specified outcomes because the proportions of macronutrients are significant. the primary objective is to detect differences in weight gain.

there will be randomized sequential assignment of pregnant women at the initial clinic visit to diet a, a high proportion of calories from refined grains as a carbohydrate source, and diet b, a high proportion of calories from whole grains. random number assignment is impractical for counseling purposes and blinding not possible. therefore, randomization by diet assignment by day of initial visit via random number was chosen. if the random number is odd diet a would be selected, if the random number is even diet b will be selected for that day.

Eligibility criteria:
inclusion criteria: * all normal pregnant patients who will be more than three months from term exclusion criteria: * illness making it a high risk pregnancy * chronic renal disease * malignancy * congestive heart failure * diabetes * hypertension
coblation tonsillotomy versus radiofrequency and cold knife dissection tonsillectomy

Conditions: Chronic Tonsillitis

Summary: this study aims to assess and compare the outcomes between coblation intracapsular tonsillotomy versus extracapsular radiofrequency and cold knife dissection tonsillectomy efficacy in managing patients requiring tonsil surgery as regards (time of operation, intraoperative blood loss, postoperative pain, postoperative bleeding, complications, tonsillar fossa healing)


Eligibility criteria:
inclusion criteria: recurrent acute tonsillitis tonsillitis resulting in febrile convulsions enlarged tonsils that cause upper airway obstruction, dysphagia, sleep disorders chronic tonsillitis chronic or recurrent tonsillitis in a streptococcal carrier not responding to beta-lactamase-resistant antibiotics exclusion criteria: patients with known bleeding disorders acute infections of tonsil contraindications for general anesthesia anemia patients unwilling or unable to give informed consent were excluded from this study patients
study in participants with heart failure with preserved ejection fraction (hfpef)

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Summary: a phase 1, open label, multiple ascending dose study to assess safety and tolerability of stm-01 in participants with heart failure with preserved ejection fraction (hfpef)


Eligibility criteria:
major inclusion criteria: * stable new york heart association (nyha) class ii or iii hf diagnosis, evident at least 6 months prior to enrolment as confirmed by medical history. * documented prior objective evidence of heart failure * screening ejection fraction ≥50%. * adequate bone marrow reserve and organ function at the screening * receiving standard of care heart failure therapy at stable doses for at least 30 days prior to screening. major exclusion criteria: * participant in any other study and has received any other investigational drug within 30 days prior to screening or 5-half-lives, whichever is longer, or any other investigational implanted device within 30 days prior to screening, or are taking part in a nonmedication study which, in the opinion of the investigator, would interfere with study compliance or outcome assessments. * prior diagnosis of hypertrophic cardiomyopathy or a known infiltrative or storage disorder causing hfpef and/or cardiac hypertrophy, such as amyloidosis, fabry disease, or noonan syndrome with lv hypertrophy. * persistent or permanent atrial fibrillation and is not therapeutically anticoagulated for at least the 4 weeks prior to the initial screening visit or is not adequately rate controlled within 6 months prior to informed consent according to investigator discretion. * other medical or psychiatric conditions that, in the opinion of the investigator, would preclude obtaining voluntary consent/assent or would confound the objectives of the study.
the effects of telerehabilitation in chronic hemiplegic patients

Conditions: Hemiplegia

Summary: the present study was conducted to investigate the effects of telerehabilitation on upper extremity functions and activities of daily living in chronic hemiplegic patients.

a total of 40 chronic hemiplegic subjects were included in the study. the patients were divided into 2 groups by simple randomization method. as the telerehabilitation group (tr), group 1 completed the treatment program, which included upper extremity and lower extremity strengthening exercises, for eight weeks, three days a week for 45-60 minutes, 10 repetitions, with online supervision. group 2 was planned as a face-to-face training group and the same exercises were performed in the clinical setting, accompanied by a physiotherapist. the evaluations were made before and after the treatment. the modified ashworth scale was used for upper extremity spasticity evaluation. the wolf motor function test was used to evaluate upper extremity functionality. the barthel adl index was used to evaluate activities of daily living (adl). the brunnstrom staging survey was used to evaluate the level of motor recovery. the treatment satisfaction inquiry survey was used to evaluate the satisfaction of the patients with the treatment method. heart rate (hr) values and oxygen saturation (sao2) were measured with pulse oximetry to monitor vital signs.

Eligibility criteria:
inclusion criteria: * having been diagnosed with stroke between the ages of 40-70 * it has been 12 months since the stroke * individuals with upper extremity spasticity level (modified ashworth scale (mas) score ≤ 3) * hand and upper extremity values above 3 according to brunnstrom motor staging * individuals with ischemic, middle cerebral artery involvement will be taken. exclusion criteria: * having advanced apraxia and aphasia * patients who do not have the cooperation to perform verbal commands and exercise training * patients who have undergone any botulinum toxin application in the last 6 months * patients with significant visual and hearing loss * individuals who do not have the necessary technological competence to provide remote video communication at home will not be accepted.

Keywords: fuctionallity chronic hemiplegia spastisity tele-rehabilitation upper extremity
acute effect of crocus sativus on postprandial glycemia

Conditions: Potential Abnormality of Glucose Tolerance; Appetitive Behavior; Blood Pressure

Summary: this study investigated the effects of two different doses of crocus sativus in glucose beverages on glycemic responses.

this study examined the short-term effects of two different doses (15 mg and 30 mg) of crocus sativus in glucose beverages on postprandial glycemic responses in healthy young adults.

Eligibility criteria:
inclusion criteria: * healthy * non-smoking * non-diabetic men and women * body mass index (bmi) between 18.5 and 24.9 kg/m2 * normal blood pressure exclusion criteria: * severe chronic disease (e.g., coronary heart disease, diabetes mellitus, kidney or liver conditions, endocrine conditions) * gastrointestinal disorders * pregnancy * lactation * competitive sports * alcohol abuse * drug dependency * allergy in crocus sativus

Keywords: crocus sativus blood glucose responses blood pressure subjective appetite blood glucose concentrations
is initial response to low dose risperidone predictive for outcome in anxiety?

Conditions: Anxiety State

Summary: risperidone at low dosage is often used as treatment of acute anxiety symptom. however, patients may be either responder or not. here we hypothesized that the early response to a low dose of risperidone is predictive to risperidone efficiency. subjects with acute anxiety symptoms (hospital anxiety depression scale) and risperidone prescription would be proposed to be enrolled in the study. a check-up is made at d0, then the subjects begin the treatment (0.5mg risperidone). the same check-up is carried out on the following day (d1). the subjects fulfil a last check-up 12 week after the beginning of treatment (w12). during the d1-w12, the psychiatrist may changes the treatment.

risperidone at low dosage is often used as treatment of acute anxiety symptom. however, patients may be either responder or not. here we hypothesized that the early response to a low dose of risperidone is predictive to risperidone efficiency. subjects with acute anxiety symptoms (hospital anxiety depression scale) and risperidone prescription would be proposed to be enrolled in the study. after acceptation, the fulfil questionnaires (mini, pcl-s-v) then they interacts with test on computers (pvt, 2nback, iowa gambling task) and give saliva and receive an actimetric watch (d0). they begin the treatment on the evening (0.5mg risperidone/day). the following day, they come back to hospital and they fulfil the same tests, questionnaires and samples (d1). 12 week after, they come again to hospital to fulfil the same tests, questionnaires and samples (w12). between d1 and s12, the psychiatrist may change the treatment, adding other treatment or modifying risperidone treatment (increasing dosage up to 2mg/day or removing it).

Eligibility criteria:
inclusion criteria: * anxiety (score above 11 at anxiety scale of hads) * to have a prescription for 0.5 mg risperidone/day * to give the consent * to have a social protection * to be adult (18-50 years) exclusion criteria: * psychiatric antecedents * any treatment for mental disease (antidepressant, anxiolytics, etc.) * ongoing neurological pathologies * scheduled surgery * addiction * pregancy * known intolerance to risperidone * participation to another biomedical study

Keywords: risperidone anxiety cognition stress
a pilot study to assess theragnostically planned liver radiation to optimize radiation therapy

Conditions: Liver Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma

Summary: the purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer. one treatment plan will be created using routine procedures and scans normally performed for radiation treatment planning. the other treatment plan will be created using routine procedures with the addition of two imaging scans; a hida (hepatobiliary iminodiacetic acid) scan and an mri (magnetic resonance imaging) scan. this study will evaluate if adding these imaging scans to treatment planning can reduce the amount of radiation to healthy liver tissue during treatment.


Eligibility criteria:
inclusion criteria * subjects must be ≥ 18 years of age at the time of signing informed consent * diagnosis of primary liver malignancy (including hepatocellular carcinoma \[hcc\] or cholangiocarcinoma) or liver metastasis from any primary solid tumor site by characteristic imaging findings on ct or mri, clinical presentation, and/or pathologic confirmation of diagnosis. * subjects with other current or prior malignancies are eligible for this study. * patients with liver metastases must have at least one of the following clinical factors that may affect liver function: 1. history of liver resection (at any time) 2. history of cirrhosis (any cause), fatty liver disease, or hepatic insufficiency due to any cause 3. prior radiation to the upper abdomen including radioembolization * ecog (zubrod) performance status 0-2. * subjects must have a child-turcotte-pugh (ctp) score ≤ 7 to be eligible. * patients who have been previously treated with non-sbrt liver directed therapies may be enrolled on study. at least 3 months must have elapsed between the most recent liver-directed therapy and study entry. * ability to provide written informed consent and hipaa authorization * subjects with an allergy to contrast agents may be enrolled at the treating physician's discretion with appropriate pre-treatment and symptom management. exclusion criteria * subjects who are pregnant or planning to become pregnant during the study. women of child bearing potential must have a negative pregnancy test * subjects must not have received chemotherapy within 2 weeks of planned 1st day of rt. * no more than 3 lesions may be treated. the maximum sum of the diameter(s) of the lesion(s) must be ≤6 cm * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (or infections requiring systemic antibiotic treatment), active upper gi ulceration or hemorrhage, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would in the opinion of the investigator limit compliance with study requirements

Keywords: radiation treatment
feeding intervention for infants with crying

Conditions: Crying

Summary: the purpose of the study is to assess if infants who have excessive crying and fussing have less of these symptoms when fed a formula containing a probiotic compared to those fed a standard infant formula.


Eligibility criteria:
inclusion criteria: * full term infants greater than or equal to 37 wks gestation * 3 weeks to less than or equal to 4 months of age upon enrollment * experiencing ongoing crying and fussy episodes of a minimum of 3 hours of crying /day for 3 days in a week for at least one week prior to enrollment * otherwise healthy as reported by parent/caregiver * is under the care of a pediatrician or other qualified healthcare professional and has had at least one postnatal visit * taking no more than one feeding of breast milk per day * having not initiated weaning foods or beverages other than infant formula or breast milk * study explained and written information provided with parent/caregiver demonstrating understanding of the given information * informed consent signed(parent/legal representative) exclusion criteria: * chromosomal or major congenital anomalies * known cow's milk allergy * receiving any type of therapeutic formula (including extensively hydrolyzed formula or free amino acid formula) * receiving an antibiotic or probiotic in the week prior to enrollment * complicated reflux, defined by reflux combined with inadequate growth and/or respiratory complications * infant's family, who in the investigator's assessment, cannot be expected to comply with the protocol * infant currently participating in another conflicting clinical study

Keywords: infants formula probiotic crying
effect of trendelenburg positioning on anesthesia-induced hypotension in elderly patients

Conditions: Hypotension on Induction; Old Age

Summary: this study investigated the effect of trendelenburg position on preventing post-induction hypotension in elderly patients undergoing abdominal surgery with general anesthesia. the patients will receive the 10° trendelenburg position or supine position during anesthesia induction. the primary outcome is the area under a mean arterial pressure (map) below 65 mm hg within the first 15 minutes during anesthesia induction.


Eligibility criteria:
inclusion criteria: * patients aged 65-90 years * scheduled for abdominal surgery with general anesthesia * expected to have continuous radial arterial pressure monitoring * american society of anesthesiologists (asa) physical status i to iii exclusion criteria: * contraindications or failure of radial arterial catheterization * expected possible difficult airway * non-sinus rhythm * increased intracranial pressure * patients at high risk of regurgitation or aspiration * inability to provide consent
quality control of ce-certified phonak hearing aids - 2020_26

Conditions: Hearing Loss

Summary: phonak hearing devices pass through different development and study phases. at an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. if the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, resulting from the pre-validation studies, they get optimized. prior to product launch, the phonak hearing systems get reviewed by a final quality control in terms of clinical trials. this is a validation study, investigating improved algorithms, features, functions and wearing comfort. this will be a clinical investigation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).

this study will investigate the combination of the features to determine if the audiological performance and quality of the new successor of the marvel family shows an improved benefit over phonak audéo marvel before going into the system validation. therefore this study will be a comparative study. the study will determine if hearing impaired users wearing the successor hearing aids, have better initial acceptance with the new precalculation, better sound quality and speech intelligibility, more clarity and loudness comfort in soft and loud environments compared to phonak marvel ric (receiver in channel) hearing aids. another objective of the study is to compare the listening effort with the two different study devices.

Eligibility criteria:
inclusion criteria: * hearing loss range: n3-n4 * experienced hearing aid user * willingness to wear behind the ear hearing aids * informed consent as documented by signature exclusion criteria: * the audiogram is not in the fitting range of the intended hearing aid * first time user * limited mobility and not in the position to attend weekly appointments in stäfa (switzerland) * participant is not able to describe experiences and hearing impressions * allergies against the material of the hearing aid
intravenous versus subcutaneous amifostine in prevention of xerostomia after rt for head and neck carcinomas

Conditions: Head and Neck Cancer

Summary: prospective randomized study in order to compare intravenous versus subcutaneous administration of amifostine in patients receiving radiotherapy for head and neck cancer. salivary flow will be evaluated during few years after the treatment by a clinical evaluation, the measure of the weight of saliva and a patient benefit questionnaire cotation.

prospective randomized study in order to compare intravenous (iv) versus subcutaneous (sc) administration of amifostine in patients receiving radiotherapy for head and neck cancer. iv administration of amifostine is 200 mg/m2/day in a short 3-min infusion 15 to 30 min before each fraction of radiotherapy. sc administration is 500mg/day in two slow 1.25 ml injections at two different sites 20 to 60 min before each radiotherapy fraction. procedure requires antiemetic treatment and blood pressure monitoring in both arms.

Eligibility criteria:
inclusion criteria: * newly diagnosed squamous cell head and neck cancer * inclusion of at least 75% of both parotid glands within radiation fields that would receive at least 40 gy * neutrophils ≥ 2000 / mm, platelets ≥ 100,000 / mm3, creatinine \< 130 / mmol.l-1, transaminase ≤ 3 x upper limit exclusion criteria: * distant metastases * prophylactic use of pilocarpine * concomitant chemotherapy

Keywords: head and neck cancer radiotherapy xerostomia randomized trial